Mea Kākau: Gregory Harris
Lā O Ka Hana: 10 Apelila 2021
HōʻAno Hou I Ka Lā: 11 Mei 2025
Anonim
L-Триптофан и 5-HTP что это? Как принимать от депрессии, бессонницы и для похудения?
Wikiō: L-Триптофан и 5-HTP что это? Как принимать от депрессии, бессонницы и для похудения?

Anter

5-HTP (5-hydroxytr Egyptophan) kahi huahana kemika o ka poloka hale kūkulu ʻo L-tryptophan. Hoʻopuka ʻia ia mea kālepa mai nā ʻanoʻano o kahi mea kanu ʻApelika i kapa ʻia ʻo Griffonia simplicifolia.

Hoʻohana ʻia ʻo 5-HTP no nā maʻi hiamoe e like me ka hiamoe, kaumaha, hopohopo, a me nā ʻano ʻē aʻe he nui, akā ʻaʻohe hōʻike ʻepekema maikaʻi e kākoʻo i ka hapa nui o kēia mau hoʻohana.

Nā Laʻau Laʻau Kūlohelohe Kūlohelohe nā helu kūpono e pili ana i nā hōʻike ʻepekema e like me ka pālākiō e hiki mai ana: Ka maikaʻi, ka hopena maikaʻi, ka hopena maikaʻi, ka hopena maikaʻi ʻole, ka maikaʻi ʻole, ka maikaʻi ʻole, a me ka lawa ʻole o nā hōʻike i ka helu.

Nā helu kūpono no 5-HTP penei:

E kūpono paha no ...

  • Kaumaha. Lawe i ka 5-HTP e ka waha e hoʻomaikaʻi i nā ʻōuli o ke kaumaha i kekahi poʻe. Hōʻike kekahi mau noiʻi noiʻi e lawe ana i ka 5-HTP e ka waha he mea maikaʻi paha e like me kekahi mau lāʻau antidepressant kuhikuhi no ka hoʻomaikaʻi ʻana i nā hōʻailona kaumaha. I ka hapanui o nā noi ʻana, 150-800 mg i kēlā me kēia lā o 5-HTP i lawe ʻia. I kekahi mau hihia, ua hoʻohana ʻia nā lāʻau kiʻekiʻe.

ʻAʻole kūpono paha no ...

  • Down syndrome. Hōʻike kekahi mau noiʻi e hāʻawi ana i ka 5-HTP i nā pēpē me Down Syndrome e hoʻomaikaʻi paha i ka mākala a me ka hana. Hōʻike nā noiʻi ʻē aʻe ʻaʻole ia e hoʻomaikaʻi i ka mākala a i ʻole ke hoʻomohala ke lawe ʻia mai ka wā kamaliʻi a hiki i ka 3-4 mau makahiki. Hōʻike pū kekahi nā noiʻi e lawe ana i ka 5-HTP me nā lāʻau lapaʻau maʻamau e hoʻomaikaʻi i ka hoʻomohala ʻana, nā mākau pilikanaka, a i ʻole nā ​​mākau ʻōlelo.

ʻAʻole lawa nā hōʻike e hōʻike i ka pono no ...

  • Ke ʻano o ka hopohopo i kaha ʻia e nā manaʻo hou a me nā ʻano hana hou (obsessive-compulsive maʻi a i ʻole OCD). Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP me ka lāʻau antidepressant fluoxetine (Prozac) no 12 mau pule e hoʻomaikaʻi ai i kekahi mau ʻōuli o OCD.
  • Hoʻohana maʻi ʻalekohola. Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP me D-phenylalanine a me L-glutamine no 40 mau lā e hiki ai ke hōʻemi i nā hōʻailona haʻalele ʻana i ka waiʻona. Eia naʻe, ʻo ka lawe ʻana i 5-HTP me carbidopa i kēlā me kēia lā no hoʻokahi makahiki ʻaʻole ia e kōkua i ka poʻe e hōʻoki i ka inu. ʻAʻole maopopo ka hopena o 5-HTP wale no ka waiʻona.
  • Maʻi Alzheimer. Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP e ka waha ʻaʻole ia e kōkua i nā hōʻailona o ka maʻi Alzheimer.
  • Hopohopo. ʻAʻole maopopo nā hōʻike e pili ana i nā hopena o 5-HTP no ka hopohopo. Hōʻike ka noiʻi mua i ka lawe ʻana i 25-150 mg o 5-HTP e ka waha i kēlā me kēia lā me ka carbidopa e hōʻemi ana i nā ʻōuli o ka hopohopo i ka poʻe me nā maʻi hopohopo. Eia nō naʻe, hōʻike kahi noiʻi ʻē aʻe i ka lawe ʻana i nā kaola ʻoi loa o 5-HTP, 225 mg i kēlā me kēia lā a ʻoi paha, e like me ka mea e hoʻonui ai i ka hopohopo. Eia kekahi, ʻo ka lawe ʻana i 60 mg o 5-HTP i kēlā me kēia lā ma o ka aa koko ʻaʻole ia e hōʻemi i ka hopohopo i ka poʻe me nā maʻi panic.
  • Hoʻopilikia ka lolo e pili ana i ka neʻe ʻana o ka mākala (cerebellar ataxia). ʻAʻole maopopo nā hōʻike e pili ana i ka hoʻohana ʻana o 5-HTP no ka ata ceria cerebellar. Hōʻike nā hōʻike mua i ka lawe ʻana i 5 mg / kg o 5-HTP i kēlā me kēia lā no 4 mau mahina e hiki ai ke hōʻemi i ka hana ʻōnaehana nerve. Eia nō naʻe, hōʻike ʻia kahi noiʻi ʻē aʻe i ka lawe ʻana i ka 5-HTP i kēlā me kēia lā a i hoʻokahi makahiki ʻaʻole e hoʻomaikaʻi i nā ʻōuli o cerebellar ataxia.
  • ʻO Fibromyalgia. Hōʻike ka noiʻi mua i ka lawe ʻana i 100 mg o 5-HTP e ka waha ʻekolu manawa i kēlā me kēia lā no 30-90 mau lā e hoʻomaikaʻi ai i ka ʻeha, palupalu, hiamoe, hopohopo, luhi, a me ka ʻoʻoleʻa kakahiaka i ka poʻe me fibromyalgia.
  • Nā ʻōuli o ka menopause. Hōʻike ka ʻimi noiʻi mua i ka lawe ʻana i 150 mg o 5-HTP i kēlā me kēia lā no 4 mau pule ʻaʻole e hoʻemi i nā wela wela i nā wahine postmenopausal.
  • ʻO Migraine. ʻAʻole maopopo nā hōʻike e pili ana i nā hopena o 5-HTP no ka pale a me ka mālama ʻana i ka migraines i nā mākua. Hōʻike kekahi mau noiʻi i ka lawe ʻana i 5-HTP i kēlā me kēia lā ʻaʻole e hoʻemi i ka migraines, ʻoiai e hōʻike ana nā noiʻi ʻē aʻe he maikaʻi paha e like me nā lāʻau lapaʻau. ʻAʻole like ka 5-HTP i mea e hōʻemi ai i ka migraines i nā keiki.
  • Ka momona. Hōʻike ka noiʻi mua i ka lawe ʻana i 5-HTP i mea e hōʻemi ai i ka makemake, ka ʻai ʻana o ka caloric, a me ke kaupaona i nā poʻe momona. Hōʻike nā noiʻi ʻē aʻe i ka hoʻohana ʻana i kahi ʻūlū waha kikoʻī nona ka 5-HTP a me nā mea unuhi ʻē aʻe (5-HTP-Nat Exts, Medestea Biotech S.p.a., Torino, ʻItalia) no 4 mau pule e hoʻonui ai i ka pohō kaumaha ma kahi o 41% i nā wahine postmenopausal nui.
  • Ka haʻalele ʻana mai heroin, morphine, a me nā lāʻau opioid ʻē aʻe. Hōʻike ka noiʻi mua i ka lawe ʻana i 200 mg o 5-HTP i kēlā me kēia lā no 6 mau lā me ka tyrosine, phosphatidylcholine, a me L-glutamine, e hōʻemi paha i ka hiamoe ʻole a me nā hōʻailona haʻalele i ka loaʻa hou ʻana o nā addict heroin.
  • Maʻi ʻo Parkinson. Hōʻike ka noiʻi mua i ka lawe ʻana i ka 100-150 mg o 5-HTP e ka waha i kēlā me kēia lā me nā lāʻau maʻamau e hōʻemi i ka haʻalulu, akā hoʻomau mau kēia mau pōmaikaʻi a hiki i 5 mau mahina. Hōʻike nā noiʻi ʻē aʻe i ka lawe ʻana i 50 mg o 5-HTP i kēlā me kēia lā e hōʻemi paha i nā ʻōuli o ka neʻe ʻana mai ka lāʻau levodopa, a me nā ʻōuli o ke kaumaha, i ka poʻe me ka maʻi Parkinson. Akā ʻo ka lawe ʻana i nā lāʻau nui o 5-HTP, 275-1500 mg i kēlā me kēia lā, me ka carbidopa e hoʻomāhuahua ai i kekahi mau ʻōuli.
  • ʻEha poʻo hina. Hōʻike ka noiʻi mua i ka lawe ʻana i 100 mg o 5-HTP ʻekolu mau manawa i kēlā me kēia lā no 8 mau pule ʻaʻole e hoʻēmi i ka ʻeha a me ka lōʻihi o nā headache tension.
  • Ka maʻi deficit-hyperactivity maʻi (ADHD).
  • ʻO Insomnia.
  • ʻO ka maʻi maʻi maʻi ʻole Premenstrual (PMDD).
  • Premenstrual Syndrome (PMS).
  • ʻO Ramsey-Hunt maʻi.
  • Nā kūlana ʻē aʻe.
Pono nā hōʻike hou aʻe e helu i ka pono o 5-HTP no kēia mau hoʻohana.

Hana ka 5-HTP i ka lolo a me ka ʻōnaehana waena e ka hoʻonui ʻana i ka hana o ka serotonin kemika. Hiki i ka Serotonin ke hoʻopili i ka hiamoe, ka makemake, ka mahana, ka moekolohe a me ka ʻeha. Ma muli o ka hoʻonui ʻana o 5-HTP i ka synthesist o serotonin, hoʻohana ʻia ia no nā maʻi he nui kahi i manaʻo ʻia he koʻikoʻi ka serotonin e like me ke kaumaha, ka hiamoe, ka momona, a me nā kumu ʻē aʻe he nui.

Ke lawe ʻia e ka waha: 5-HTP ʻo ia SAFE MAU PONO ke lawe pono ʻana ma ka waha. Hoʻohana palekana ʻia ia i nā kaona a i ka 400 mg i kēlā me kēia lā a i hoʻokahi makahiki. Akā ʻo kekahi poʻe i lawe i 5-HTP ua hoʻomohala i kahi kūlana i kapa ʻia ʻo eosinophilia-myalgia syndrome (EMS). He kūlana koʻikoʻi ʻo EMS e pili ana i ka palupalu o ka nāhelehele (myalgia) a me nā mea kūpono ʻole o ke koko (eosinophilia). Manaʻo kekahi poʻe ua hoʻokumu ʻia ʻo EMS e kahi mea hana kuʻuna ʻole a haumia paha i kekahi huahana 5-HTP. Akā ʻaʻole lawa nā hōʻike ʻepekema e ʻike inā e hoʻokumu ʻia ʻo EMS e 5-HTP, kahi mea haumia, a i ʻole kekahi mea ʻē aʻe. A hiki i ka ʻike hou aku, 5-HTP e hoʻohana akahele.

ʻO nā hopena ʻē aʻe o 5-HTP e komo pū me ka puʻuwai puʻuwai, ʻeha o ka ʻōpū, nausea, ka luaʻi, ka palahē, ka hiamoe, nā pilikia moekolohe, a me nā pilikia o ka mākala.

5-HTP ʻo POSSIBLY UNSAFE ke lawe ʻia e ka waha i nā kaha nui. Hoʻohui ʻia nā hana mai 6-10 mau lā i nā pilikia o ka ʻōpū koʻikoʻi a me nā spasms muscle.

Nā mālama a me nā ʻōlelo aʻoaʻo kūikawā:

Hāpai a me ka hānai umauma: ʻAʻole lawa ka ʻike pono e ʻike inā palekana ʻo 5-HTP e hoʻohana i ka wā hāpai a hānai umauma paha. Noho ma ka ʻaoʻao palekana a pale i ka hoʻohana.

Nā keiki: 5-HTP ʻo ia SAFE MAU PONO ke lawe ʻia e ka waha kūpono. Hoʻohana palekana ʻia nā hana a i 5 mg / kg i kēlā me kēia lā a hiki i 3 mau makahiki i nā pēpē a me nā keiki a hiki i ka 12-makahiki. E like me ka poʻe mākua, aia kekahi hopohopo e pili ana i ka hiki no ka eosinophilia-myalgia syndrome (EMS) i loko o nā keiki, kahi ʻano koʻikoʻi e pili ana i ka palupalu o nā mākala (myalgia) a me nā mea ʻino o ke koko (eosinophilia).

ʻOki kino: 5-HTP hiki ke hoʻopili i kahi kemika lolo i kapa ʻia serotonin. ʻO kekahi mau lāʻau i lawelawe ʻia i ka wā o ke ʻoki ʻana hiki ke hoʻololi i ka serotonin. Lawe i ka 5-HTP ma mua o ke kahakaha ʻana i kumu nui ai ka serotonin i ka lolo a hiki i nā hopena hopena koʻikoʻi me nā pilikia puʻuwai, haʻalulu, a me ka hopohopo. E haʻi i nā mea maʻi e hōʻoki i ka lawe ʻana i 5-HTP ma ka liʻiliʻi he 2 mau pule ma mua o ke kaha ʻana.

Mekia
Mai lawe i kēia hui ʻana.
Nā lāʻau no ke kaumaha (MAOI)
Hoʻonui ka 5-HTP i kahi kemika i ka lolo i kapa ʻia serotonin. Hoʻonui kekahi mau lāʻau i hoʻohana ʻia no ke kaumaha e hoʻonui ai i ka serotonin. Lawe iā 5-HTP me kēia mau lāʻau i hoʻohana ʻia no ke kaumaha e hoʻonui ai i ka serotonin. Hiki i kēia ke kumu i nā hopena ʻino e pili ana i ka ʻeha poʻo, nā pilikia puʻuwai, haʻalulu, huikau, a me nā hopohopo

ʻO kekahi o kēia mau lāʻau i hoʻohana ʻia no ke kaumaha me phenelzine (Nardil), tranylcypromine (Parnate), a me nā mea ʻē aʻe.
Kānāwai
E akahele me kēia hui ʻana.
Carbidopa (Lodosyn)
Hiki i ka 5-HTP ke hoʻopili i ka lolo. Hiki i ka Carbidopa (Lodosyn) ke hoʻopili i ka lolo. Lawe i ka 5-HTP me ka carbidopa hiki ke hoʻonui i ka hopena o nā hopena ʻē aʻe e like me ka ʻōlelo wikiwiki, ka hopohopo, ka huhū, a me nā mea ʻē aʻe.
Nā lāʻau lapaʻau hōʻoluʻolu (depressants CNS)
5-HTP paha ke kumu o ka hiamoe a me ka hiamoe. ʻO nā lāʻau i kumu e hiamoe ai i kapa ʻia ʻo nā mea hōʻohi. Lawe i ka 5-HTP me nā lāʻau hoʻohiamoe e hoʻonāukiuki paha.

ʻO kekahi mau lāʻau hoʻohiehie e komo pū me clonazepam (Klonopin), lorazepam (Ativan), phenobarbital (Donnatal), zolpidem (Ambien), a me nā mea ʻē aʻe.
Nā lāʻau Serotonergic
5-HTP hiki ke hoʻonui i kahi kemika i ka lolo i kapa ʻia serotonin. Hoʻonui pū kekahi mau lāʻau i ka serotonin. Lawe i ka 5-HTP me kēia mau lāʻau e hoʻonui ai i ka serotonin. Hiki i kēia ke kumu i nā hopena ʻino e pili ana i ka ʻeha poʻo, nā pilikia puʻuwai, haʻalulu, huikau, a me nā hopohopo.

ʻO kekahi o kēia mau lāʻau e pili pū ana me fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Tofranil), sumatriptan (Imitrex), zolmitriptan (Zomig), rizatran methadone (Dolophine), tramadol (Ultram), a me nā mea ʻē aʻe he nui.
Nā mea kanu a me nā mea hoʻopihapiha me nā mea hoʻohiamoe
Hiki i ka 5-HTP ke hana i ka hiamoe a hiamoe paha. Ke hoʻohana nei ia me nā mea kanu a me nā mea hoʻopili ʻē aʻe i like ka hopena e hopena i ka hiamoe nui. ʻO kekahi o kēia mau mea kanu a me nā mea hoʻopihapiha me ka calamus, California poppy, catnip, hops, Jamaican dogwood, kava, St. John's wort, skullcap, valerian, yerba mansa, a me nā mea ʻē aʻe.
Nā mea kanu a me nā mea hoʻopihapiha me nā waiwai serotonergic
Hoʻonui ka 5-HTP i kahi kemikolo lolo i kapa ʻia serotonin. Lawe i ka 5-HTP me nā mea kanu a me nā mea hoʻopili ʻē aʻe e hoʻonui i ka serotonin e alakaʻi i ka serotonin he nui a hana i nā hopena me nā pilikia puʻuwai, haʻalulu a me ka hopohopo. ʻO nā mea kanu a me nā mea hoʻopihapiha ʻē aʻe e hoʻonui ai i ke kiʻekiʻe o ka serotonin e komo pū ana me ka pēpē pēpē Hawaiʻi, L-tryptophan, S-adenosylmethionine (SAMe), a me ko St.
ʻAʻole ʻike ʻia nā launa me nā meaʻai.
Ua aʻo ʻia nā mahele aʻe i ka noiʻi ʻepekema: NA MAKAHIKI

E ka waha:
  • No ke kaumaha: ʻO ka mea maʻamau, lawe ʻia ka 150-800 mg i kēlā me kēia lā no 2-6 mau pule. Hoʻokaʻawale ʻia kēia mau kaha a lawelawe ʻia e like me 50 mg i 100 mg ʻekolu mau manawa i ka lā. I kekahi manawa hoʻomaka ka mahele haʻahaʻa a hoʻonui mau i kēlā me kēia 1-2 mau pule a hiki i ka hōʻili ʻia ʻana o kahi lāʻau. ʻO ka liʻiliʻi, hoʻohana ʻia nā lāʻau kiʻekiʻe. I hoʻokahi aʻo, hoʻonui mau ʻia ka lāʻau i 3 gram i kēlā me kēia lā.
2-Amino-3- (5-Hydroxy-1H-Indol-3-yl) ʻO Propanoic Acid, 5 Hydroxy-Tryptophan, 5 Hydroxy-Tryptophane, 5-Hydroxytr Egyptophan, 5-Hydroxytr Egyptophane, 5-Hydroxy L-Tryptophan, 5-Hydroxy L-Tryptophane, 5-Hydroxy Tryptophan, 5-L-Hydroxytr Egyptophan, L-5 HTP, L-5-Hydroxytr Egyptophan, L-5-Hydroxytr Egyptophane, Oxitriptan.

E aʻo hou aʻe ai pehea i kākau ʻia ai kēia ʻatikala, e ʻoluʻolu e ʻike i ka Nā Laʻau Laʻau Kūlohelohe Kūlohelohe ʻano hana.


  1. Meloni M, Puligheddu M, Sanna F, et al. Ka maikaʻi a me ka palekana o 5-Hydroxytr Egyptophan ma luna o ka levodopa i hoʻokomo ʻia i nā pilikia ma ka maʻi ʻo Parkinson: kahi ʻike mua. ʻO J Neurol Sci. 2020; 415: 116869. Nānā kiʻi ʻole.
  2. Yousefzadeh F, Sahebolzamani E, Sadri A, et al. 5-Hydroxytr Egyptophan ma ke ʻano he adjuvant therapy i ka hoʻomaʻamaʻa ʻana i ka maʻi maʻamau a koʻikoʻi paha: kahi hoʻokolokolo kaulua makapō makapō me ka kaʻi o ka placebo. Int Clin Psychopharmacol. 2020; 35: 254-262. Nānā kiʻi ʻole.
  3. Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Nā hopena o 5-hydroxytr Egyptophan ma nā ʻano like ʻole o ke kaumaha: kahi loiloi ʻōnaehana a me nā meta-analysis. Nutr Rev 2020; 78: 77-88. Nānā kiʻi ʻole.
  4. Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, Defazio G. Ka maikaʻi a me ka palekana o 5-hydroxytr Egyptophan ma ke kaumaha a me ka apathy i ka maʻi o Parkinson: kahi ʻike mua. Eur J Neurol 2020; 27: 779-786. Nānā kiʻi ʻole.
  5. Israeliana N, Del Colle A, Li Z, et al. Nā hopena o Serotonin a me Slow-Release 5-Hydroxytr Egyptophan ma Gastrointestinal Motility i kahi Kiʻina Kiʻi o ke kaumaha. Gastroenterology. 2019; 157: 507-521.e4. Nānā kiʻi ʻole.
  6. ʻO Michelson D, ʻAoʻao SW, Casey R, et al. ʻO kahi maʻi eosinophilia-myaligia e pili ana i ka maʻi e pili ana i ka hōʻike ʻana i ka l-5-hydroxytr Egyptophan. ʻO J Rheumatol 1994; 21: 2261-5. Nānā kiʻi ʻole.
  7. Lemaire PA, Adosraku RK. ʻO kahi hana HPLC no ka hoʻāʻo pololei o ka prerororor precursor, 5-hydroxytrophan, i nā hua o Griffonia simplicifolia. Phytochem Anal 2002; 13: 333-7.
  8. ʻO Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S. Ka pilina ma waena o ka lawe ʻia ʻana o 5-hydroxytr Egyptophan mai kahi papaʻai i hoʻohui ʻia, ma o Griffonia simplicifolia extract, a me ka hopena o ka māʻona i nā wahine ʻoi ke kaumaha ma hope o ka hoʻoponopono ʻana o ka waha. Eʻai i ka hoʻokaumaha kaumaha 2012; 17: e22-8. Nānā kiʻi ʻole.
  9. Pardo JV. Mania e pili ana i ka hoʻohui o ka hydroxytr Egyptophan i ka monoamine oxidase inhibitor. ʻO Gen Hosp Psychiatry 2012; 34: 102.e13-4.
  10. Chen D, Liu Y, He W, Wang H, Wang Z. Neurotransmitter-precursor-supplement interven for detoxified heroin addicts. ʻO J Huazhong Univ Sci Technolog Med Med 2012; 32: 422-7.
  11. ʻO Gendle MH, Young EL, Romano AC. Nā hopena o ka 5-hydroxytr Egyptophan waha ma ka hana hoʻolālā maʻamau: ʻike i nā pilina dopamine / serotonin hiki i ka forebrain. Hum Psychopharmacol 2013; 28: 270-3.
  12. ʻO ka hālāwai o ke Kōmike aʻoaʻo aʻoaʻo aʻoaʻo ʻo US Food and Drug Administration June 17-18, 2015. Loaʻa ma: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycomm Komiti/ucm455276.pdf (kiʻi ʻia 8/21/15).
  13. ʻO ka US Food and Drug Administration. Nā inoa a me nā ʻae a nā keiki makua ʻole. Loaʻa ma: www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (kiʻi ʻia 8/20/2015).
  14. ʻO Das YT, Bagchi M, Bagchi D, Preuss HG. Ka palekana o 5-hydroxy-L-tryptophan. ʻO Toxicol Lett 2004; 150: 111-22. Nānā kiʻi ʻole.
  15. Weise P, Koch R, Shaw KN, Rosenfeld MJ. ʻO ka hoʻohana ʻana o 5-HTP i ka mālama ʻana i ka Down Syndrome. Nā Pediatrics 1974; 54165-8. Nānā kiʻi ʻole.
  16. ʻO Bazelon M, Paine RS, Cowie VA, et al. ʻO ka hoʻohuli hou ʻana o ka hiponia i nā pēpē me Down's syndrome e ka hoʻomalu ʻana o 5-hydroxytr Egyptophan. Lancet 1967; 1: 1130-3. Nānā kiʻi ʻole.
  17. Sano I. ʻO ka hoʻōla o ke kaumaha me L-5-hydroxytr Egyptophan (L-5-HTP). ʻO Psychiatria et Neurologia Japonicas 1972; 74: 584.
  18. Klein P, Lees A, a me Stern G. Nā hopena o ka 5-hydroxytr Egyptophan mau i ka parkinsonian instability o ka hele a me ke kaulike a me nā maʻi neurological ʻē aʻe. Adv Neurol 1986; 45: 603-604.
  19. VanPraag, H. M. a me Korf, J. 5-Hydroxytr Egyptophan ma ke ʻano he antidepressant: Ka wānana waiwai o ka hoʻāʻo probenecid. Psychopharmacol.Bull. 1972; 8: 34-35.
  20. ʻO Sicuteri F. 5-hydroxytr Egyptophan i ka prophylaxis o ka migraine. Nā kamaʻilio noiʻi noiʻi lāʻau lapaʻau 1972; 4: 213-218.
  21. Rosano Burgio, F., Borgatti, R., Scarabello, E., a me Lanzi, G. Headache i nā keiki a me nā ʻōpio. Nā hana o ka International International Symposium ma Headache ma nā keiki a me nā Adolecents. 1989; 339-47.
  22. Mathew NT. 5-hydroxytr Egyptophan i ka prophylaxis o migraine: kahi hoʻopaʻa makapō makapō. Headache 1978; 18: 111.
  23. ʻO De Benedittis G, ʻo Massei R. 5-HT i mua o ka migraine prophylaxis: kahi papa pālua makapō makapō me L-5-hydroxytr Egyptophan. ʻO Clin J Pain 1986; 2: 123-129.
  24. ʻO Wyatt, R. J., Vaughan, T., Kaplan, J., Galanter, M., a me Green, R. 5-Hydroxytr Egyptophan a me schizophrenia mau. I: Barchas J a me Usdin E. Serotonin a me ke ʻano. Nu Ioka: Hale Paʻi ʻĀpelika; 1973.
  25. ʻO Brodie HKH, Sack R, a me Siever L. Ke aʻo maʻi ʻana o L-5-hydroxytr Egyptophan i ke kaumaha. I: Barchas J a me Usdin E. Serotonin a me ka lawena. Nu Ioka: Hale Paʻi Kula; 1973.
  26. ʻO Auffret, M., Comte, H., a me Bene, J. Eosinophilia-myalgia maʻi i hoʻokomo ʻia e L-5 hydroxytr Egyptophane: ʻekolu paha mau hihia. Fund Clinac Pharmacol 2013; Mea hoʻolako 1: poster P2-204.
  27. Cangiano C, Laviano A, Del Ben M, et al. Nā hopena o ka 5-hydroxy-tryptophan waha ma ka lawe ʻana i ka ikehu a me ke koho macronutrient i nā maʻi diabetic non-insulin hilinaʻi. Int J Obes Relat Metab Disord 1998; 22: 648-54. Nānā kiʻi ʻole.
  28. Ju, C. Y. a me Tsai, C. T. Serotonergic ʻano hana i komo i ka suppression o ka hānai ʻana e 5-HTP i nāʻiole. Chin J Physiol 1995; 38: 235-240. Nānā kiʻi ʻole.
  29. Pranzatelli, M. R., Tate, E., Galvan, I., a me Wheeler, A. He hoʻokolokolo hoʻokolokolo ʻia o 5-hydroxy-L-tryptophan no ka ataxia i ka myoclonus epilepsy holomua. ʻO Clin Neurol.Neurosurg. 1996; 98: 161-164. Nānā kiʻi ʻole.
  30. Frith, C. D., Johnston, E. C., Joseph, M. H., Powell, R. J., a me Watts, R. W. Hoʻokolokolo ʻelua makapō makapō o 5-hydroxytr Egyptophan i kahi hihia o Lesch- Nyhan syndrome. ʻO J Neurol Neurosurg. Psychiatry 1976; 39: 656-662. Nānā kiʻi ʻole.
  31. ʻO Bastard, J., Truelle, J. L., a me Emile, J. [Ka hopena o 5 hydroxy-tryptophan i ka maʻi ʻo Parkinson]. ʻO Nouv Presse Med 9-11-1976; 5: 1836-1837. Nānā kiʻi ʻole.
  32. Trouillas P, Serratrice G, Laplane D, et al. Keʻano Levorotatory o 5-hydroxytr Egyptophan ma Friedreich's ataxia. Nā hopena o kahi noiʻi noiʻi lāʻau lāʻau makapō makapō-makapō. Arch Neurol 1995; 52: 456-60. Nānā kiʻi ʻole.
  33. Wessel K, Hermsdörfer J, Deger K, et al. Ke aʻo crossover makapō makapō me ke ʻano levorotatory o hydroxytr Egyptophan i nā mea maʻi me nā maʻi cerebellar degenerative. Arch Neurol 1995; 52: 451-5. Nānā kiʻi ʻole.
  34. Alino, J. J., Gutierrez, J. L., a me Iglesias, M. L. 5-Hydroxytr Egyptophan (5-HTP) a me kahi MAOI (nialamide) i ka mālama ʻana i nā kaumaha. ʻO kahi hoʻopaʻa ʻana i hoʻomalu ʻia me ka makapō makapō. Int Pharmacopsychiatry 1976; 11: 8-15. Nānā kiʻi ʻole.
  35. Pranzatelli, M. R., Tate, E., Huang, Y., Haas, R. H., Bodensteiner, J., Ashwal, S., a me Franz, D. Neuropharmacology o ka myoclonus epilepsy holomua: pane i 5- hydroxy-L-tryptophan. Epilepsia 1995; 36: 783-791. Nānā kiʻi ʻole.
  36. Thomson, J., Rankin, H., Ashcroft, GW, Yates, CM, McQueen, JK, a me Cummings, SW Ka mālama ʻana i ke kaumaha i ka hana maʻamau: kahi hoʻohālikelike o L-tryptophan, amitriptyline, a me kahi hui o L-tryptophan a me amitriptyline me ka placebo. Psychol Med 1982; 12: 741-751. Nānā kiʻi ʻole.
  37. Trouillas, P., Garde, A., Robert, JM, Renaud, B., Adeleine, P., Bard, J., a me Brudon, F. [Ka hoʻi ʻana o ka maʻi cerebellar ma lalo o ka manawa lōʻihi o 5-HTP a i ʻole ka hoʻohui o 5-HTP a me benserazide. 26 mau helu i helu ʻia a mālama ʻia me ka hoʻohana ʻana i nā ʻano kamepiula]. Rev Neurol. (Paris) 1982; 138: 415-435. Nānā kiʻi ʻole.
  38. ʻO Thal, L. J., Sharpless, N. S., Wolfson, L., a me Katzman, R. Hoʻomaʻamaʻa ʻana i ka myoclonus me L-5-hydroxytr Egyptophan a me carbidopa. Ann Neurol 1980; 7: 570-576. Nānā kiʻi ʻole.
  39. van Hiele LJ. l-5-Hydroxytr Egyptophan i ke kaumaha: ʻo ka therapist substitusi mua loa i ka psychiatry? ʻO ka mālama ʻana i nā mea maʻi he 99 i waho me nā ʻehaʻeha kūpaʻa. Neuropsychobiology 1980; 6: 230-40. Nānā kiʻi ʻole.
  40. Magnussen, I.a me Nielsen-Kudsk, F. Bioavailability a me nā pharmacokinetics e pili ana i ke kanaka o L-5-hydroxytr Egyptophan i lawelawe waha ʻia i ka mokuʻāina paʻa. Acta Pharmacol Toxicol. (Copenh) 1980; 46: 257-262. Nānā kiʻi ʻole.
  41. Trouillas, P., Garde, A., Robert, J. M., a me Adeleine, P. [Ka hoʻi ʻana o ke kanaka cerebellar ataxia ma lalo o ka manawa lōʻihi o 5-hydroxytr Egyptophan]. C.R.Seances Acad Sci III 1-5-1981; 292: 119-122. Nānā kiʻi ʻole.
  42. ʻO Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-hydroxytr Egyptophan a me pyridoxine. ʻO ko lākou hopena i nā keiki ʻōpio me Down's Syndrome. ʻO Am J Dis Child 1980; 134: 838-44. Nānā kiʻi ʻole.
  43. Longo G, Rudoi I, Iannuccelli M, Strinati R, Panizon F. [Hoʻomaʻamaʻa i ka maʻi headache nui i ka makahiki ulu me L-5-HTP (keʻa i ka hoʻopaʻa makapō makapō me ka placebo) Pediatr Med Chir 1984; 6: 241-5. Nānā kiʻi ʻole.
  44. ʻO Bono, G., Micieli, G., Sances, G., Calvani, M., a me Nappi, G. L-5HTP i mālama ʻia i nā poʻo hina mua: kahi hoʻāʻo e hōʻike i ka ʻike maʻi o nā mea maʻi pane. Cephalalgia 1984; 4: 159-165. Nānā kiʻi ʻole.
  45. ʻO Quadbeck, H., Lehmann, E., a me Tegeler, J. Hoʻohālikelike o ka hana antidepressant o ka tryptophan, tryptophan / 5- hydroxytr Egyptophan hoʻohui a me ka nomifensine. Neuropsychobiology 1984; 11: 111-115. Nānā kiʻi ʻole.
  46. van Praag, H. M. I ka ʻimi ʻana i ke ʻano o ka hana o nā antidepressants: 5-HTP / tyrosine mixtures i ke kaumaha. ʻO Adv Biochem Psychopharmacol. 1984; 39: 301-314. Nānā kiʻi ʻole.
  47. ʻO Trouillas P. Ka hoʻi ʻana o ka maʻi cerebellar me ka hoʻoponopono lōʻihi o 5-HTP a i ʻole ka hui pū ʻana o 5-HTP-benserazide: 21 mau hihia me nā ʻōuli helu i hana ʻia e ka kamepiula. Ital J Neurol Sci 1984; 5: 253-266. Nānā kiʻi ʻole.
  48. van Praag, H. M. a me de Haan, S. Chemoprophylaxis o nā kaumaha. ʻO kahi hoʻāʻo e hoʻohālikelike i ka lithium me 5- hydroxytr Egyptophan. ʻO Acta Psychiatr. Pūʻali Kūʻai 1981; 290: 191-201. Nānā kiʻi ʻole.
  49. van Praag, H. a me de Hann, S. Pōʻino kaumaha a me 5-hydroxytr Egyptophan prophylaxis. ʻO Psychiatry Res. 1980; 3: 75-83. Nānā kiʻi ʻole.
  50. Soulairac, A. [Ka hana hypnotic o mecloqualone. Hoʻohālikelike me nā hopena placebo a me secobarbital]. Presse Med 4-10-1971; 79: 817-818. Nānā kiʻi ʻole.
  51. Chase, T. N., Ng, L. K., and Watanabe, A. M. Parkinson's disease. Hoʻololi e 5-hydroxytr Egyptophan. ʻO Neurology 1972; 22: 479-484. Nānā kiʻi ʻole.
  52. ʻO Wyatt, R. J., Vaughan, T., Galanter, M., Kaplan, J., a me Green, R. Hoʻololi i ka lawena o nā mea maʻi schizophrenic mau i hāʻawi ʻia iā L-5- hydroxytr Egyptophan. ʻEpekema 9-22-1972; 177: 1124-1126. Nānā kiʻi ʻole.
  53. van Praag HM, Korf J, Dols LC, Schut T. He pailota hoʻopaʻa haʻawina o ka wānana waiwai o ka probenecid hōʻike i ka noi ʻana o 5-hydroxytr Egyptophan ma ke ʻano he antidepressant. ʻO Psychopharmacologia 1972; 25: 14-21. Nānā kiʻi ʻole.
  54. Zarcone, V., Kales, A., Scharf, M., Tan, T. L., Simmons, J. Q., a me Dement, W. C. Hoʻokomo ʻia ka waha waha o 5-hydroxytr Egyptophan. ʻO ka hopena ma ka lawena a me nā hana hiamoe i nā keiki schizophrenic ʻelua. Arch Gen Psychiatry 1973; 28: 843-846. Nānā kiʻi ʻole.
  55. ʻO Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, EH, a me Marsden, CD Clinical, biochemical, a me nā hiʻohiʻona physiological e hoʻomaopopo ana i ka myoclonus e pane i ka 5-hydroxytr Egyptophan, tryptophan me kahi monoamine oxidase mea kāohi, and clonazepam. ʻO Brain 1977; 100: 455-487. Nānā kiʻi ʻole.
  56. Van Woert, M. H., Rosenbaum, D., Howieson, J., a me Bowers, M. B., Jr. Lohi lōʻihi o ka myoclonus a me nā maʻi neurologic ʻē aʻe me L-5- hydroxytr Egyptophan a me carbidopa. N Engl J Med 1-13-1977; 296: 70-75. Nānā kiʻi ʻole.
  57. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5HTP i ke kūpikipiki kū ʻole i nā mea hōʻoki hou. ʻO kahi noi hoʻohālikelike hāmama me tranylcypromine. Br J Psychiatry 1985; 147: 16-22. Nānā kiʻi ʻole.
  58. ʻO De Benedittis G, ʻo Massei R. Serotonin i mua o ka maʻi poʻo hina mua. ʻO kahi hoʻopaʻa pālua makapō makapō me L-5-hydroxytr Egyptophan vs. placebo. ʻO J Neurosurg Sci 1985; 29: 239-48. Nānā kiʻi ʻole.
  59. ʻO Titus F, Dávalos A, Alom J, Codina A. 5-Hydroxytr Egyptophan me methysergide i ka prophylaxis o ka migraine. Hoʻokolokolo hoʻokolohua kaulike ʻia. Eur Neurol 1986; 25: 327-9. Nānā kiʻi ʻole.
  60. ʻO Santucci M, Cortelli P, Rossi PG, Baruzzi A, Sacquegna T. L-5-hydroxytr Egyptophan me kahi placebo i ka migraine prophylaxis ʻōpio: he noi crossover makapō makapō. Cephalalgia 1986; 6: 155-7. Nānā kiʻi ʻole.
  61. ʻO Irwin, M. R., Marder, S. R., Fuentenebro, F., a me Yuwiler, A. L-5-hydroxytr Egyptophan hoʻonāukiuki i nā hōʻailona psychotic maikaʻi i hoʻokomo ʻia e D-amphetamine. ʻO Psychiatry Res. 1987; 22: 283-289. Nānā kiʻi ʻole.
  62. Angst J, Woggon B, Schoepf J. Ka mālama ʻana i ke kaumaha me L-5-hydroxytr Egyptophan versus imipramine. Nā hualoaʻa o ʻelua wehe a hoʻokahi aʻo ʻana makapō makapō. Arch Psychiatr Nervenkr 1977; 224: 175-86. Nānā kiʻi ʻole.
  63. Kahn RS, Westenberg HG, Verhoeven WM, et al. Ka hopena o kahi preconoror serotonin a lawe i ka mea kāohi i nā maʻi hopohopo; ka hoʻohālikelike makapō-pālua o 5-hydroxytr Egyptophan, clomipramine a me placebo. Int Clin Psychopharmacol 1987; 21: 33-45. Nānā kiʻi ʻole.
  64. ʻO De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S. Headache i ka hui pū ʻana me nā maʻi hiamoe o nā keiki: kahi loiloi psychodiagnostic a me ka hoʻokele hoʻokolohua hoʻokolohua - L-5-HTP versus placebo. Nā lāʻau lapaʻau Exp Clin Res 1987; 13: 425-33. Nānā kiʻi ʻole.
  65. Zmilacher, K., Battegay, R., a me Gastpar, M. L-5-hydroxytr Egyptophan wale nō a me ka hui pū ʻana me ka mea hoʻopuni decarboxylase peripheral i ka mālama ʻana i ke kaumaha. Neuropsychobiology 1988; 20: 28-35. Nānā kiʻi ʻole.
  66. Nolen, W. A., van de Putte, J. J., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., a me Haffmans, J. Hoʻolālā hoʻolālā i ke kaumaha. II. ʻO nā mea kāohi MAO i ke kaumaha e kūpaʻa i nā antidepressants cyclic: ʻelua mau noiʻi crossover i kāohi ʻia me tranylcypromine me L-5-hydroxytr Egyptophan a me nomifensine. ʻO Acta Psychiatr. Manaʻo 1988; 78: 676-683. Nānā kiʻi ʻole.
  67. Kaneko M, Kumashiro H, Takahashi Y, Hoshino Y. L-5HTP lapaʻau a me ka pae 5-HT serum ma hope o ka hoʻouka ʻana o L-5-HTP i nā mea maʻi kaumaha. Neuropsychobiology 1979; 5: 232-40. Nānā kiʻi ʻole.
  68. Rousseau JJ. Nā hopena o kahi levo-5-hydroxytr Egyptophan-dihydroergocristine hui pū ʻia me ke kaumaha a me ka hana neuropsychic: kahi hoʻokolohua hoʻokolohua hoʻokolohua hoʻokolohua lua-makapō i nā maʻi ʻelemakule. ʻO Clin Ther 1987; 9: 267-72. Nānā kiʻi ʻole.
  69. Anders, T. F., Cann, H. M., Ciaranello, R. D., Barchas, J. D., a me Berger, P. A. ʻO nā mea i ʻike hou ʻia e pili ana i ka hoʻohana ʻana o 5-hydroxytr Egyptophan i kahi keiki me ka maʻi Lesch-Nyhan. Neuropadiatrie. 1978; 9: 157-166. Nānā kiʻi ʻole.
  70. Ceci F, Cangiano C, Cairella M, et al. Nā hopena o ka hoʻoponopono 5-hydroxytr Egyptophan waha e pili ana i ka hana hānai ʻana i nā kumuhana wahine makua makua. ʻO J Neural Transm 1989; 76: 109-17. Nānā kiʻi ʻole.
  71. Jangid P, Malik P, Singh P, Sharma M, Gulia AK. Ke aʻo hoʻohālikelike o ka pono o l-5-hydroxytr Egyptophan a me fluoxetine i nā mea maʻi e hōʻike nei me ka pae depressive mua. ʻO Asian J Psychiatr 2013; 6: 29-34. Nānā kiʻi ʻole.
  72. Zarcone, V. P., Jr. a me Hoddes, E. Nā hopena o 5-hydroxytr Egyptophan ma ka ʻāpana o ka hiamoe Rem i nā mea ʻona ʻona. ʻO Am J Psychiatry 1975; 132: 74-76. Nānā kiʻi ʻole.
  73. ʻO Opladen, T., Hoffmann, G. F., a me Blau, N. ʻO kahi ana honua no nā mea maʻi me nā hemahema tetrahydrobiopterin e hōʻike nei me hyperphenylalaninaemia. ʻO J Inherit. Metab Dis 2012; 35: 963-973. Nānā kiʻi ʻole.
  74. Baraldi, S., Hepgul, N., Mondelli, V., a me Pariante, C. M. ʻO ka hoʻomaʻamaʻa simptomatik o ke kaumaha i loko o ka maʻi interferon-alpha i loko o ka hepatitis C: kahi loiloi ʻōnaehana. ʻO J Clin Psychopharmacol. 2012; 32: 531-543. Nānā kiʻi ʻole.
  75. Pan, L., McKain, BW, Madan-Khetarpal, S., Mcguire, M., Diler, RS, Perel, JM, Vockley, J., a me Brent, DA GTP-cyclohydrolase deficit pane i sapropterin a me 5-HTP supplementation : ke kōkua o ke kaumaha-refrakst depression a me ke ʻano suicidal. Nānā BMJ.Rep. 2011; 2011 Nānā abstract.
  76. Friedman, J., Roze, E., Abdenur, JE, Chang, R., Gasperini, S., Saletti, V., Wali, GM, Eiroa, H., Neville, B., Felice, A., Parascandalo, R., Zafeiriou, DI, Arrabal-Fernandez, L., Dill, P., Eichler, FS, Echenne, B., Gutierrez-Solana, LG, Hoffmann, GF, Hyland, K., Kusmierska, K., Tijssen, MA, Lutz, T., Mazzuca, M., Penzien, J., Poll-The BT, Sykut-Cegielska, J., Szymanska, K., Thony, B., a me Blau, N. Sepiapterin hōʻemi hoʻoliʻiliʻi: kahi mālama mimic o ka maʻi lolo. Ann Neurol. 2012; 71: 520-530. Nānā kiʻi ʻole.
  77. ʻO Jukic T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. Ka hoʻohana ʻana i kahi meaʻai me D-phenylalanine, L-glutamine a me L-5-hydroxytriptophan i ka hoʻopau ʻana i nā hōʻailona haʻalele i ka waiʻona. Coll Antropol 2011; 35: 1225-30. Nānā kiʻi ʻole.
  78. ʻO Sarris, ʻo J. Clinical depression: kahi hōʻike hōʻike e pili ana i ka hoʻopili ʻia ʻana o ka lāʻau lapaʻau. ʻO Altern .her. ʻO Med Med. 2011; 17: 26-37. Nānā kiʻi ʻole.
  79. ʻO Dill, P., Wagner, M., Somerville, A., Thony, B., Blau, N., a me Weber, P. Neurology kamaliʻi: paʻakikī ʻo paroxysmal, nānā i luna, a me hyponia: nā hiʻohiʻona o ka hemahema o ka sepiapterin reductase. Neurology 1-31-2012; 78: e29-e32. Nānā kiʻi ʻole.
  80. Horvath, GA, Selby, K., Poskitt, K., Hyland, K., Waters, PJ, Coulter-Mackie, M., a me Stockler-Ipsiroglu, SG Hemiplegic migraine, ka hopu ʻana, nā spares paraparesis holomua, nā maʻi maʻi, a me ke koma i nā kaikaina me ka serotonin ʻōnaehana haʻahaʻa. Cephalalgia 2011; 31: 1580-1586. Nānā kiʻi ʻole.
  81. Morrison, K. E. ʻO ke kaʻina genome āpau e hoʻomaopopo i ka mālama ʻana: hana ka lāʻau pilikino i kahi ʻē aʻe i mua. ʻO Clin Chem 2011; 57: 1638-1640. Nānā kiʻi ʻole.
  82. Bainbridge, MN, Wiszniewski, W., Murdock, DR, Friedman, J., Gonzaga-Jauregui, C., Newsham, I., Reid, JG, Fink, JK, Morgan, MB, Gingras, MC, Muzny, DM, Hoang, LD, Yousaf, S., Lupski, JR, a me Gibbs, RA Ke kaʻina genome āpau no ka hoʻokele maikaʻi ʻana o ka mea maʻi. Unuhi ʻo Sci. Med 6-15-2011; 3: 87re3. Nānā kiʻi ʻole.
  83. den Boer JA, Westenberg HG. Nā hopena Behavioural, neuroendocrine, a me nā hopena biochemical o 5-hydroxytr Egyptophan lawelawe i ka maʻi panic. ʻO Psychiatry Res 1990; 31: 267-78. Nānā kiʻi ʻole.
  84. Adamsen, D., Meili, D., Blau, N., Thony, B., a me Ramaekers, V. Autism e pili ana me ka 5-hydroxyindolacetic acid haʻahaʻa ma CSF a me ka genter heterozygous SLC6A4 Gly56Ala a me nā mea hoʻolaha hoʻolaha 5-HTTLPR L / L . Mol. Genet. Metab 2011; 102: 368-373. Nānā kiʻi ʻole.
  85. Cross, D. R., Kellermann, G., McKenzie, L. B., Purvis, K. B., Hill, G. J., a me Huisman, H. A randomized target amino acid therapy with behaviourally at-risk adopter. ʻO Dev Ke olakino mālama keiki. 2011; 37: 671-678. Nānā kiʻi ʻole.
  86. ʻO Gendle, M. H. a me Golding, A. C. Hoʻokele waha o 5-hydroxytr Egyptophan (5-HTP) hoʻopilikia i ka hoʻoholo ʻana ma lalo o ke ʻano kānalua akā ʻaʻole ma lalo o ka makaʻu: nā hōʻike mai ka Iowa Gambling Task. Hum Psychopharmacol. 2010; 25: 491-499. Nānā kiʻi ʻole.
  87. ʻO Iovieno, N., Dalton, E. D., Fava, M., a me Mischoulon, D. Nā antidepressants kūlohelohe ʻelua: loiloi a me nā loiloi. J Pili. Disord. 2011; 130: 343-357. Nānā kiʻi ʻole.
  88. Leu-Semenescu, S., Arnulf, I., Decaix, C., Moussa, F., Clot, F., Boniol, C., Touitou, Y., Levy, R., Vidailhet, M., a me Roze, E. Nā hiamoe a me nā hopena hopena o kahi genetically induced loss of serotonin. Hiamoe 3-1-2010; 33: 307-314. Nānā kiʻi ʻole.
  89. Freedman RR. ʻO ka mālama ʻana i nā uila wela menopausal me 5-hydroxytr Egyptophan. Maturitas 2010; 65: 383-5. Nānā kiʻi ʻole.
  90. Nā pule hebedoma, B. S. Formulated o nā mea hoʻopihapihaʻai a me nā mea kanu lāʻau no ka hoʻomaha a me ka hana anxiolytic: Relarian. ʻO Med Sci Monit. 2009; 15: RA256-RA262. Nānā kiʻi ʻole.
  91. Rondanelli M, Klersy C, Iadarola P, et al. ʻO ka māʻona a me ka amino-acid profile i nā wahine kaona kaupaona ma hope o kahi hoʻomaʻamaʻa hou e hoʻohana ana i kahi mea kanu kūlohelohe i ka unuhi sublingual. Int J Obes (Lond) 2009; 33: 1174-1182. Nānā kiʻi ʻole.
  92. Maissen CP, Ludin HP. [Hoʻohālikelike i ka hopena o 5-hydroxytr Egyptophan a me propranolol i ka lawelawe waena o ka migraine]. ʻO Schweiz Med Wochenschr 1991; 121: 1585-90. Nānā kiʻi ʻole.
  93. Shell W, Bullias D, Charuvastra E, et al. ʻO ka hoʻāʻo ʻana, kahi placebo-kāohi hoʻokolohua o kahi amino acid hoʻomākaukau i ka manawa a me ka maikaʻi o ka hiamoe. 'Am J Ther 2010; 17: 133-9. Nānā kiʻi ʻole.
  94. Trujillo-Martin, M. M., Serrano-Aguilar, P., Monton-Alvarez, F., a me Carrillo-Fumero, R. Ka hopena a me ka palekana o nā mālama no nā ataxias degenerative: kahi ʻōnaehana loiloi. ʻO Mov Disord. 6-15-2009; 24: 1111-1124. Nānā kiʻi ʻole.
  95. Rothman, R. B. Hoʻomaʻamaʻa i ka momona me ka "hoʻohui" ʻo ka lāʻau lapaʻau. ʻO Am J Ther 2010; 17: 596-603. Nānā kiʻi ʻole.
  96. Chae, HS, Kang, OH, Choi, JG, Oh, YC, Lee, YS, Jang, HJ, Kim, JH, Park, H., Jung, KY, Sohn, DH, a me Kwon, DY 5-hydroxytr Egyptophan e hana ma ʻo ka mitogen-activated protein kinase extracellular-signal regulated protein kinase pathway e hoʻololi i ka cyclooxygenase-2 a me ka inducible nitric oxide synthase expression i nā RAW 264.7 pūnaewele. Biol Pharm Bull 2009; 32: 553-557. Nānā kiʻi ʻole.
  97. ʻO Hendricks, E. J., Rothman, R. B., a me Greenway, F. L. Pehea e hoʻohana ai nā kauka lapaʻau ʻoi o ka momona i nā lāʻau e mālama i ka momona. Kaona. (Kālā. Puna) 2009; 17: 1730-1735. Nānā kiʻi ʻole.
  98. Longo, N. Nā maʻi o ka metabolism biopterin. ʻO J Inherit. Metab Dis 2009; 32: 333-342. Nānā kiʻi ʻole.
  99. ʻO Pons, R. The phenotypic spectrum of pediatric neurotransmitter maʻi a me ka pēpē parkinsonism. ʻO J Inherit. Metab Dis 2009; 32: 321-332. Nānā kiʻi ʻole.
  100. Schaefer, M., Winterer, J., Sarkar, R., Uebelhack, R., Franke, L., Heinz, A., a me Friebe, A. ʻEkolu mau hihia o ka tryptophan add-on a monotherapy o ka hepatitis C a me IFNalpha -e hoʻopili i nā maʻi maʻi. Nā Psychosomatics 2008; 49: 442-446. Nānā kiʻi ʻole.
  101. ʻO Jacobsen, JP, Nielsen, EO, Hummel, R., Redrobe, JP, Mirza, N., a me Weikop, P. Ka noʻonoʻo ʻole o nā ʻiole NMRI i nā mea hōʻoki hou i nā serotonin e koho ʻia i ka hoʻāʻo ʻana o ka huelo e hiki ke hoʻohuli ʻia e ka hana pū ʻana me 5. -hydroxytr Egyptophan. Psychopharmacology (Berl) 2008; 199: 137-150. Nānā kiʻi ʻole.
  102. Liu, K. M., Liu, T. T., Lee, N. C., Cheng, L. Y., Hsiao, K. J., a me Niu, D. M. ʻO ka ukali wā lōʻihi o nā mea maʻi Kina Taiwanese i mālama mua ʻia no 6-pyruvoyl-tetrahydropterin synthase deficit. Arch Neurol. 2008; 65: 387-392. Nānā kiʻi ʻole.
  103. Horvath, GA, Stockler-Ipsiroglu, SG, Salvarinova-Zivkovic, R., Lillquist, YP, Connolly, M., Hyland, K., Blau, N., Rupar, T., a me nā wai, PJ Autosomal recessive GTP cyclohydrolase I ka nele me ka ʻole o hyperphenylalaninemia: hōʻike o ka hoʻomau phenotypic ma waena o nā mana nui a me nā recessive. Mol. Genet. Metab 2008; 94: 127-131. Nānā kiʻi ʻole.
  104. ʻApōpō, J. D., Vikraman, S., Imeri, L., a me Opp, M. R. Nā hopena o ka hoʻōla serotonergic e 5-hydroxytr Egyptophan i ka hiamoe a me ka mahana o ke kino o C57BL / 6J a me nāʻiole interleukin-6-hemahema ka mahele a me ka manawa e pili ana. Hiamoe 1-1-2008; 31: 21-33. Nānā kiʻi ʻole.
  105. Meolie, AL, Rosen, C., Kristo, D., Kohrman, M., Gooneratne, N., Aguillard, RN, Fayle, R., Troell, R., Townsend, D., Claman, D., Hoban, T., a me Mahowald, M. Lapaʻau lāʻau ʻole no ka hiamoe ʻole: kahi loiloi o nā huahana me nā hōʻike palena palena. J Clin. Hiamoe Med 4-15-2005; 1: 173-187. Nānā kiʻi ʻole.
  106. Cangiano C, Ceci F, Cairella M, et al. Nā hopena o 5-hydroxytr Egyptophan i ka ʻai ʻana i ka lawena a me ka mālama ʻana i nā kuhikuhi papaʻai i nā kumuhana makua makua. Adv Exp Med Biol 1991; 294: 591-3. Nānā kiʻi ʻole.
  107. Petre-Quadens, O. lāua ʻo De Lee, C. 5-Hydroxytr Egyptophan a hiamoe ma Down's syndrome. ʻO J Neurol Sci 1975; 26: 443-453. Nānā kiʻi ʻole.
  108. Lesch, K. P., Hoh, A., Disselkamp-Tietze, J., Wiesmann, M., Osterheider, M., a me Schulte, H. M. 5-Hydroxytr Egyptamine1A pane pane i ka mea loaʻa i ka maʻi obsessive-compulsive. Hoʻohālikelike o nā mea maʻi a me nā kaohi. ʻO Arch Gen Psychiatry 1991; 48: 540-547. Nānā kiʻi ʻole.
  109. ʻO Halladay, AK, Wagner, GC, Sekowski, A., Rothman, RB, Baumann, MH, a me Fisher, H. Alterations i ka inu waiʻona, ka hopu ʻana i ka hopu ʻana, a me ka lawe ʻana o monoamine i nāʻiole i mālama ʻia me phentermine a me 5-hydroxy-L-tryptophan . Synaps 2006; 59: 277-289. Nānā kiʻi ʻole.
  110. Curcio, J. J., Kim, L. S., Wollner, D., a me Pockaj, B. A. ʻO ka hiki o 5-hydryoxytr Egyptophan no ka hoʻoliʻiliʻi wela wela: kahi kuhiakau. Altern Med Rev 2005; 10: 216-221. Nānā kiʻi ʻole.
  111. ʻO Victor, S. a me Ryan, ʻo S. W. Nā lāʻau no ka pale ʻana i ka huhū o ka migraine i nā keiki. ʻO Cochrane Database.Syst.Rev 2003;: CD002761. Nānā kiʻi ʻole.
  112. ʻO George DT, Lindquist T, Rawlings RR, et al. Mālama ʻo Pharmacologic i ka pale i nā mea maʻi me ka waiʻona: ʻaʻohe hopena o 5-hydroxytr Egyptophan a i ʻole levodopa. ʻO Clin Pharmacol Ther 1992; 52: 553-60. Nānā kiʻi ʻole.
  113. Shaw, K., Turner, J., a me Del Mar, C. Tryptophan a me 5-hydroxytr Egyptophan no ke kaumaha. ʻO Cochrane Pūnaewele. Syst Rev 2002;: CD003198. Nānā kiʻi ʻole.
  114. Ciaranello, R. D., Anders, T. F., Barchas, J. D., Berger, P. A., a me Cann, H. M. Ka hoʻohana ʻana o 5-hydroxytr Egyptophan i kahi keiki me ka maʻi Lesch-Nyhan. Keiki Psychiatry Hum Hum 1976; 7: 127-133. Nānā kiʻi ʻole.
  115. Anderson, L. T., Herrmann, L., a me Dancis, J. Ka hopena o L-5-hydroxytr Egyptophan i ka pilikino ponoʻī i ka maʻi ʻo Lesch-Nyhan: kahi hōʻike maikaʻi ʻole. Neuropadiatrie. 1976; 7: 439-442. Nānā kiʻi ʻole.
  116. ʻO Growdon, J. H., Young, R. R., a me Shahani, B. T. L-5-hydroxytr Egyptophan i ka mālama ʻana i kekahi mau syndrome ʻokoʻa kahi i kaulana ai ka myoclonus. ʻO Neurology 1976; 26: 1135-1140. Nānā kiʻi ʻole.
  117. ʻO Takahashi S, Kondo H, Kato N. Ka hopena o l-5-hydroxytr Egyptophan ma ka lolo monoamine metabolism a me ka loiloi ʻana i kāna hopena maʻi i nā mea maʻi kaumaha. ʻO J Psychiatr Res 1975; 12: 177-87. Nānā kiʻi ʻole.
  118. ʻO Preshaw RM, Leavitt D, Hoag G. ʻO ke kākoʻo papaʻai 5-hydroxytr Egyptophan a me ka urinary 5-hydroxyindole acetic acid. CMAJ 2008; 178: 993. Nānā kiʻi ʻole.
  119. ʻO Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytr Egyptophan: kahi loiloi i kona pono antidepressant a me nā hopena maikaʻi ʻole. J Clin Psychopharmacol 1987; 7: 127-37 .. Nānā i ka abstract.
  120. Shaw K, Turner J, Del Mar C. Tryptophan a me 5-hydroxytr Egyptophan no ke kaumaha. ʻO Cochrane Database Syst Rev 2002;: CD003198. Nānā kiʻi ʻole.
  121. ʻO Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Ke aʻo pālua makapō o 5-hydroxytr Egyptophan me kahi placebo i ka mālama ʻana i ka maʻi fibromyalgia mua. ʻO J Int Med Res 1990; 18: 201-9. Nānā kiʻi ʻole.
  122. Johnson KL, Klarskov K, Benson LM, et al. Ke kūʻana o ka piko X a me nā mea e pili ana: ʻo ka poke i hōʻike ʻia i ka hihia e pili ana iā 5-hydroxy-L-tryptophan e pili ana me ka eosinophilia-myalgia syndrome. ʻO J Rheumatol 1999; 26: 2714-7. Nānā kiʻi ʻole.
  123. Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction a me ka hahau ʻana ma hope o ka hoʻohana ʻana i nā lāʻau serotonergic. ʻO Neurology 2002; 58: 130-3. Nānā kiʻi ʻole.
  124. U. S. ʻAi a me nā lāʻau hoʻomalu lāʻau, Center no ka palekana o ka meaʻai a me ka meaʻai pono e noi ʻia, Ke keʻena o nā huahana mea pono, ka lepili ʻana, a me nā mea hoʻohui meaʻai. Ka Pepa ʻIke Ma L-Tryptophan a me 5-hydroxy-L-tryptophan, Pepeluali 2001.
  125. Nardini M, De Stefano R, Iannuccelli M, et al. ʻO ka mālama ʻana i ke kaumaha me L-5-hydroxytr Egyptophan i hui pū ʻia me ka chlorimipramine, kahi noiʻi makapō makapō. Int J Clin Pharmacol Res 1983; 3: 239-50. Nānā kiʻi ʻole.
  126. ʻO Ribeiro CA. L-5-Hydroxytr Egyptophan i loko o ka prophylaxis o ka maʻi ahulau kūpilikiʻi mau loa: kahi makapō makapō makapō, hoʻokolohua ʻole ʻia, placebo-kāohi ʻia. Headache 2000; 40: 451-6. Nānā kiʻi ʻole.
  127. ʻO Poldinger W, Calanchini B, Schwarz W. He ʻano hana i ke kaumaha: nele i ka serotonin ma ke ʻano he syndrome target i ka hoʻohālikelike ʻana o 5-hydroxytr Egyptophan a me fluvoxamine. Psychopathology 1991; 24: 53-81. Nānā kiʻi ʻole.
  128. Sternberg EM, Van Woert MH, Young SN, et al. Ke hoʻomohala ʻana i kahi maʻi e like me ka scleroderma i ka wā o ka therapy me L-5-hydroxytr Egyptophan a me carbidopa. N Engl J Med 1980; 303: 782-7. Nānā kiʻi ʻole.
  129. ʻO ka US Food and Drug Administration. Hōʻoia nā impurities i ka papaʻai papa 5-hydroxy-L-tryptophan. Pepa kamaʻilio a FDA, ʻAukake 31, 1998; T98-48.
  130. Meyer JS, Welch KM, Deshmukh VD, et al. ʻO Neurotransmitter precursor amino acid i ka mālama ʻana i ka dementia multi-infarct a me ka maʻi ʻo Alzheimer. ʻO J Amer Geriat Soc 1977; 25: 289-98. Nānā kiʻi ʻole.
  131. ʻO Trouillas P, Brudon F, Adeleine P. Hoʻonui o ka cerebellar ataxia me ka levorotatory form o 5-hydroxytr Egyptophan: kahi papa makapō makapō me ka nui o ka hana ʻana i ka ʻikepili. Arch Neurol 1988; 45: 1217-22. Nānā kiʻi ʻole.
  132. Kahn RS, Westenberg HG. L-5-hydroxytr Egyptophan i ka mālama ʻana i nā maʻi pīhoihoi. ʻO J Affect Disord 1985; 8: 197-200. Nānā kiʻi ʻole.
  133. Cangiano C, Ceci F, Cancino A, et al. ʻO ka hana ʻana i ka lawaiʻa a me ke kūpaʻa i nā kuhikuhi papaʻai i nā mea makua makua momona i mālama ʻia me 5-hydroxytr Egyptophan. ʻO Am J Clin Nutr 1992; 56: 863-7. Nānā kiʻi ʻole.
  134. ʻO Sarzi Puttini P, Caruso I. Syndrome fibromyalgia mua a me 5-hydroxy-L-tryptophan: kahi 90 mau lā e wehe ai i kahi noiʻi. ʻO J Int Med Res 1992; 20: 182-9. Nānā kiʻi ʻole.
  135. Nakajima T, Kudo Y, Kaneko Z. ʻO ka loiloi loiloi o 5-hydroxy-L-tryptophan ma ke ʻano he lāʻau antidepressant. ʻO Folia Psychiatr Neurol Jpn 1978; 32: 223-30. Nānā kiʻi ʻole.
  136. ʻO Michelson D, ʻAoʻao SW, Casey R, et al. ʻO kahi maʻi eosinophilia-myalgia e pili ana i ka maʻi e pili ana i ka hōʻike ʻana iā L-5-hydroxytr Egyptophan. ʻO J Rheumatol 1994; 21: 2261-5. Nānā kiʻi ʻole.
  137. Manu Manu TC. 5-Hydroxytr Egyptophan: He mea hoʻomaikaʻi Serotonin Precursor. Altern Med Rev 1998; 3: 271-80. Nānā kiʻi ʻole.
Nānā hope - 12/29/2020

HoʻOmaopopo Mākou

9 Pono maikaʻi ke olakino o ke Kumina
No Kou Kino

9 Pono maikaʻi ke olakino o ke Kumina

Hoʻopili mākou i nā huahana a mākou e manaʻo nei he pono no kā mākou poʻe heluhelu. Inā kūʻai ʻoe ma o nā loulou i kēia ʻaoʻao, loaʻa iā mākou kahi kōmike liʻiliʻi. Eia kā mākou hana.ʻO Cumin kahi mea...
No ke aha kuʻu manamana wāwae nui ma kekahi ʻaoʻao?
Ola Kino

No ke aha kuʻu manamana wāwae nui ma kekahi ʻaoʻao?

Ua hele paha kēia puaʻa liʻiliʻi i ka mākeke, akā inā he manunu ma kekahi ʻaoʻao, e hopohopo nō ʻoe. Hiki i ka numbne i nā manamana wāwae ke manaʻo me he nalo lā a hapa paha o ka naʻau. Hiki iā ia ke ...